9
Participants
Start Date
July 6, 2015
Primary Completion Date
November 19, 2018
Study Completion Date
November 19, 2018
topotecan
intraparenchymally-administered topotecan will use the Cleveland Multiport Catheter to directly infuse topotecan into the tumor site of patients with suspected recurrent/progressive high grade glioma (HGG). This drug is already FDA approved to be administered intravenously.
Cleveland Multiport Catheter
The Cleveland Multiport Catheter will directly infuse topotecan into the tumor site of patients with suspected recurrent/progressive high grade glioma (HGG). Standard treatment is to adminsiter the drug intravenously.
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland
Collaborators (1)
Infuseon Therapeutics, Inc.
INDUSTRY
Michael Vogelbaum, MD, PhD
OTHER